3,4-methylenedioxymethamphetamine (MDMA, ecstasy) and driving impairment

被引:0
|
作者
Logan, BK
Couper, FJ
机构
[1] Bur Forens Lab Serv, Washington State Toxicol Lab, Washington State Patrol, Seattle, WA 98134 USA
[2] Univ Washington, Seattle, WA 98195 USA
关键词
forensic science; MDMA; ecstasy; driving impairment;
D O I
暂无
中图分类号
DF [法律]; D9 [法律]; R [医药、卫生];
学科分类号
0301 ; 10 ;
摘要
3,4-Methylenedioxymethamphetamine, or MDMA, is increasing in popularity in the United States as a drug of abuse. It has stimulant and empathogenic mood altering properties with the potential to, affect psychomotor skills and impact driving. This report reviews the literature relating to the relevant psychomotor effects of the drug, the relationship between dose and blood concentrations, and studies and case reports on specific effects of the drug on driving. The latter reports include both laboratory driving simulator studies and anecdotal reports, and case series. We also report details of eighteen cases of apparent MDMA impaired driving, including six drivers, whose blood tested positive for MDMA alone. Most subjects displayed muscle twitching and body tremors, dilated pupils, slow pupillary reaction to light, elevated pulse and blood pressure, lack of balance and coordination, and most were perspiring profusely. Five six subjects were given field sobriety tests, (one leg stand, walk and turn test), and all five performed poorly. There was no clear correlation between the blood concentration of MDMA and the specific demeanor of the subject. These findings are consistent with other reports, and lead to the conclusion that MDMA use is not consistent with safe driving, and that impairment of various types may persist for a considerable time after last use.
引用
收藏
页码:1426 / 1433
页数:8
相关论文
共 50 条
  • [1] Ecstasy: 3,4-methylenedioxymethamphetamine (MDMA)
    Morimoto, BH
    Lovell, S
    Kahr, B
    [J]. ACTA CRYSTALLOGRAPHICA SECTION C-CRYSTAL STRUCTURE COMMUNICATIONS, 1998, 54 : 229 - 231
  • [2] The Agony of Ecstasy: MDMA (3,4-Methylenedioxymethamphetamine) and the Kidney
    Campbell, Garland A.
    Rosner, Mitchell H.
    [J]. CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2008, 3 (06): : 1852 - 1860
  • [3] NEUROCHEMISTRY AND NEUROTOXICITY OF 3,4-METHYLENEDIOXYMETHAMPHETAMINE (MDMA, ECSTASY)
    MCKENNA, DJ
    PEROUTKA, SJ
    [J]. JOURNAL OF NEUROCHEMISTRY, 1990, 54 (01) : 14 - 22
  • [4] Recreational use of 3,4-methylenedioxymethamphetamine (MDMA) or 'ecstasy': evidence for cognitive impairment
    Bhattachary, S
    Powell, JH
    [J]. PSYCHOLOGICAL MEDICINE, 2001, 31 (04) : 647 - 658
  • [5] The cardiovascular effects of ecstasy (3,4-methylenedioxymethamphetamine, MDMA)
    Lester, SJ
    Baggott, MJ
    Viloria, EM
    Welm, S
    Schiller, NB
    Mendelson, J
    Jones, RT
    Foster, E
    [J]. CIRCULATION, 1999, 100 (18) : 575 - 575
  • [6] Adverse reactions with 3,4-methylenedioxymethamphetamine (MDMA; 'ecstasy')
    McCann, UD
    Slate, SO
    Ricaurte, GA
    [J]. DRUG SAFETY, 1996, 15 (02) : 107 - 115
  • [7] 3,4-methylenedioxymethamphetamine (MDMA, or ''ecstasy'') and associated hypoglycemia
    Montgomery, H
    Myerson, S
    [J]. AMERICAN JOURNAL OF EMERGENCY MEDICINE, 1997, 15 (02): : 218 - 218
  • [8] False-Positive Amphetamine/Ecstasy (MDMA/3,4-Methylenedioxymethamphetamine) (CEDIA) and Ecstasy (MDMA/3,4-Methylenedioxymethamphetamine) (DRI) Test Results With Fenofibrate
    Kaplan, Yusuf Cem
    Erol, Almila
    Karadas, Baris
    [J]. THERAPEUTIC DRUG MONITORING, 2012, 34 (05) : 493 - 495
  • [9] A review on the mitochondrial toxicity of "ecstasy" (3,4-methylenedioxymethamphetamine, MDMA)
    Capela, Joao Paulo
    Carvalho, Felix Dias
    [J]. CURRENT RESEARCH IN TOXICOLOGY, 2022, 3
  • [10] The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy")
    Green, AR
    Mechan, AO
    Elliott, JM
    O'Shea, E
    Colado, MI
    [J]. PHARMACOLOGICAL REVIEWS, 2003, 55 (03) : 463 - 508